StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

Equities researchers at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued on Sunday. The firm set a “hold” rating on the stock.

Other research analysts also recently issued reports about the stock. HC Wainwright raised their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. JMP Securities reaffirmed a “market outperform” rating and issued a $25.00 price objective on shares of DBV Technologies in a report on Tuesday, September 24th.

DBV Technologies Stock Performance

DBVT opened at $3.66 on Friday. The company has a 50 day moving average of $3.46 and a 200 day moving average of $4.10. The company has a market cap of $70.64 million, a PE ratio of -0.81 and a beta of 0.64. DBV Technologies has a 12 month low of $2.20 and a 12 month high of $10.70.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.